EcoDrugPlus

Free Fatty Acid Receptor 3

Ensembl ID : ENSELUG00000022113
Gene Symbol: LOC105007927
3 Cross references
273 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSELUG00000017840
Gene Symbol: FRK
1 Cross references
210 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSELUG00000000602
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSELUG00000021429
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSELUG00000024116
Gene Symbol: LOC105011228
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2

Ensembl ID : ENSELUG00000021951
Gene Symbol: LOC105028307
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Gamma-3

Ensembl ID : ENSELUG00000020670
Gene Symbol: LOC105022073
3 Cross references
223 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSELUG00000014803
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSELUG00000021980
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSELUG00000009373
Gene Symbol: GABRA5
3 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSELUG00000020706
Gene Symbol: GABRA5
3 Cross references
210 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSELUG00000024139
Gene Symbol: GABRA6
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).